

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for PTO Form 149/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/622,104
Filing Date	July 17, 2001
First Named Inventor	Beeley et al.
Art Unit	1639
Examiner Name	Celsa, Bennett M
Attorney Docket Number	256/153 US

Sheet 1 of 6

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
ML		US- 4,758,550	07-19-1988	Cardinaux et al.	
		US- 5,124,314	06-23-1992	Cooper, G.	
		US- 5,175,145	12-29-1992	Cooper, G.	
		US- 5,264,372	11-23-1993	Beaumont et al.	
		US- 5,266,561	11-30-1993	Cooper et al.	
		US- 5,321,008	06-14-1994	Beaumont et al.	
		US- 5,367,052	11-22-1994	Cooper et al.	
		US- 5,376,638	12-27-1994	Young et al.	
		US- 5,508,260	04-16-1996	Beaumont et al.	
		US- 5,580,953	12-03-1996	Albrecht et al.	
ML		US- 5,625,032	04-29-1997	Gaeta et al.	
		US- 5,686,411	11-11-1997	Gaeta et al.	
		US- 5,795,861	08-18-1998	Kolterman et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
ML		WO 92/11863	07-23-1992	Amylin Pharmace		
		WO 93/10147	05-27-1993	Amylin Pharmace		
		WO 93/14408	07-22-1993	Amylin Pharmace		
		WO 95/07098	03-16-1995	Amylin Pharmace		

Examiner Signature		Date Considered	11/11/05
-----------------------	--	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/622,104
Filing Date	July 17, 2001
First Named Inventor	Beeley et al.
Art Unit	1639
Examiner Name	Celsa, Bennett M
Attorney Docket Number	256/153 US

Sheet 2 of 6

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Alam et al. Biochem. Biophys. Res. Commun., 179(1):134-139 (1991)	
		Azria et al., Calcitonins - Physiological and Pharmacological Aspects, pp 24-25 New York: Springer-Verlag (1989)	
		Beaumont et al., British Journal of Pharmacology, 115(5):713-715 (1995)	
		Brain et al., Eur. Journal of Pharmacol., 183:2221 (1990)	
		Broderick et al., Biochem. Biophys. Res. Comm., 177: 932-938 (1991)	
		Brown et al., Diabetes 43 :172A Abstract # 536 (1994)	
		Chance et al., Brain Res., 539: 352-354 (1991)	
		Chantry et al., Biochem. J., 277:139-143 (1991)	
		Cooper et al., Proc. Natl. Acad. Sci., USA, 84:8628-8632 (1987)	
		Cooper et al., Proc. Natl. Acad. Sci., 85:7763-7766 (1988)	


Examiner Signature	Date Considered 7/11/05
-----------------------	----------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449 (7-99)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**



(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/622,104
Filing Date	July 17, 2001
First Named Inventor	Beeley et al.
Art Unit	1639
Examiner Name	Celsa, Bennett M
Attorney Docket Number	256/153 US

Sheet 3 of 6

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Fineman et al., Diabetes 40:30A Abstract # 0117 (1997)	
		Follett et al., Clinical Research, 39(1):39A (1991)	
		Gaeta et al., Med. Chem. Res., 3:483-490 (1994)	
		Gamse et al., J. of Bone and Mineral Research, 8 (Suppl 1):S200 (1993) Abstract #334	
		Gedulin et al., Biochem. Biophys. Res. Commun., 180(2):782-789 (1991)	
		Gedulin et al., Diabetologia 38 (Suppl1):A244 Abstract # 945 (1995)	
		Gedulin et al., Metabolism 46(1):67-70 (1997)	
		Gomez-Foix et al., Biochem J. 276:607-610 (1991)	
		Huang et al., Hypertension 19:I-101-I-109 (1992)	
		Jonderko K et al., J. of Clinical Gastroenterology 1990 United States, 12(1), 22-28 (1990).	

Examiner  
SignatureDate  
Considered

1/11/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/622,104
		Filing Date	July 17, 2001
		First Named Inventor	Beeley et al.
		Art Unit	1639
		Examiner Name	Celsa, Bennett M
Sheet 4	of 6	Attorney Docket Number	256/153 US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Koda et al., The Lancet, 339:1179-1180 (1992)	
		Kolterman et al., Diabetologia, 39:492-499 (1996)	
		Koopmans et al., Diabetologia, 34:218-224 (1991)	
		Leighton and Cooper, Nature, 335:632-635 (1988)	
		Lupien and Young, Diabetes Nutrition and Metabolism - Clinical and Experimental, 6(1) 13-18 (Feb 1993)	
		MacDonald et al., Diabetologia, 38(1):118 (1995) (abstract)	
		Molina et al., Diabetes, 39:260-265 (1990)	
		Moore et al., Biochem. Biophys. Res. Commun., 179(1):1-9 (1991)	
		Munson, Anal. Biochem., 107:220-239 (1980)	
		Nowak et al., J. Lab. Clin. Med., 123(1):110-116 (1994)	


Examiner Signature		Date Considered	11/1/05
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.





PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/622,104
		Filing Date	July 17, 2001
		First Named Inventor	Beeley et al.
		Art Unit	1639
		Examiner Name	Celsa, Bennett M
Sheet 5	of 6	Attorney Docket Number	256/153 US


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Nyholm et al., J. of Clinical Endocrinology and Metabolism, 81(3):1083-1089 (1996)	
		Ogawa et al., J. Clin. Invest., 85: 973-976 (1990)	
		Pittner et al., FEBS Letters, 365(1):98-100 (1995)	
		Pittner et al., J. of Cellular Biochemistry, 55S:19-28 (1994)	
		Plourde et al., Life Sci., 52:857-862 (1993)	
		Pozvek, Gordana et al., Molecular Pharmacology, 51(4), 658-665 (1997)	
		Prickett et al., Peptides: Chemistry, Structure and Biology, Proc. of the 14th Am. Peptide Symp., June 1995, Columbus, OH/ed. Kaumaya, P.T.P., Hodges, R.S. pp 620-622 (1996)	
		Scarpignato et al., Arch. int. Pharmacodyn. 246:286-294 (1980)	
		Silvestre et al., Reg. Pept., 31:23-31 (1990)	
		Stephens et al., Diabetes, 40:395-400 (1991)	

Examiner Signature		Date Considered	1/11/05
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**Complete if Known****INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

6

of

6

Application Number

09/622,104

Filing Date

July 17, 2001

First Named Inventor

Beeley et al.

Art Unit

1639



Examiner Name


Celsa, Bennett M

Attorney Docket Number

256/153 US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Van Valen et al., Neuroscience Letters, 119:195-198 (1990)	
		Wang et al., FEBS Letts., 291:195-198 (1991)	
		Wang et al., Technical Report No. 10, Supp. 42:28 (1988)	
		Young et al., Current Opinion in Endocrinology & Diabetes, 4(4):282-290 (1997)	
		Young et al., Mol. Cell. Endocrinol., 84:R1-R5 (1992)	
		Young et al., Am. J. Physiolog., 263(2):E274-E281 (1992)	
		Young et al., Am. J. of Physiology, 259:457-461 (1990)	
		Young et al., Diabetologia, 38:642-648 (1995)	
		Zaidi et al., Trends in Endocrinology and Metabolism, 4(8):255-259 (1993)	
		Zhu et al., Biochem. Biophys. Res. Commun., 177(2):771-776 (1991)	

Examiner  
Signature

Date

Considered

1/11/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.